ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021
The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 102 citations in OpenAlex.
- Agitation, Alzheimer's disease, and autophagy: mechanistic insights into aging pathways, gut microbiome, and artificial intelligence.Frontiers in immunology · 2026Review
- Unravelling the Viral Hypothesis of Schizophrenia: A Comprehensive Review of Mechanisms and Evidence.International journal of molecular sciences · 2025Review
- Acute Schizophrenia-like Psychotic Disorder Against the Background of COVID-19.Medicina (Kaunas, Lithuania) · 2025Observational
- Article
- COVID-19 in patients with severe mental illness: An analysis of in-patients at a psychiatric hospital in Cape Town.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2025Article
- Exploring the psychological impact of long COVID: symptoms, mechanisms, and treatments.Frontiers in psychiatry · 2025Review
- Hematological and biochemical markers and cytokine levels in hospitalized psychiatric patients with COVID-19.Frontiers in immunology · 2025Article
- Association of pre-existing depression and anxiety with Omicron variant infection.Molecular psychiatry · 2024Article
- Investigating the Role of Serotonin Levels in Cognitive Impairments Associated with Long COVID-19.Chonnam medical journal · 2024Review
- Aripiprazole as protector against COVID-19 mortality.Scientific reports · 2024Article
- Review
- Neuroleptic Malignant Syndrome Concurrent with COVID-19 Infection: A Case Report.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024Article
- COVID-19 and Mental Health: A "Pandemic Within a Pandemic".Advances in experimental medicine and biology · 2024Review
- An Adolescent Presenting With Mania and Catatonia Associated With Coronavirus Disease-2019 Encephalitis.Cureus · 2024Article
- Pupillary Light Reflex and Multimodal Imaging in Patients With Central Serous Chorioretinopathy.Investigative ophthalmology & visual science · 2023Article
- In Between the Psychological and Physiological Self - The Impact of Covid-19 Pandemic on the Neuro-Socio-Ecological and Inflammatory Mind-Body-Brain System.Clinical neuropsychiatry · 2023Article
- Cognitive Impairment in Multiple Sclerosis.Bioengineering (Basel, Switzerland) · 2023Review
- Neurological and Psychiatric Manifestations of Long COVID-19 and Their [Diagnostics (Basel, Switzerland) · 2023Review
- Acute Onset of Mania and Psychosis in the Context of Long-COVID: A Case Study.Psychiatry research case reports · 2023Article
- Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System.Biomolecules · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of the corona virus disease (COVID-19) has had major global impact. The relationship between severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection and psychiatric diseases is of great concern, with an evident link between corona virus infections and various central and peripheral nervous system manifestations. Unmitigated neuro-inflammation has been noted to underlie not only the severe respiratory complications of the disease but is also present in a range of neuro-psychiatric illnesses. Several neurological and psychiatric disorders are characterized by immune-inflammatory states, while treatments for these disorders have distinct anti-inflammatory properties and effects. With inflammation being a common contributing factor in SARS-CoV-2, as well as psychiatric disorders, treatment of either condition may affect disease progression of the other or alter response to pharmacological treatment. In this review, we elucidate how viral infections could affect pre-existing psychiatric conditions and how pharmacological treatments of these conditions may affect overall progress and outcome in the treatment of SARS-CoV-2. We address whether any treatment-induced benefits and potential adverse effects may ultimately affect the overall treatment approach, considering the underlying dysregulated neuro-inflammatory processes and potential drug interactions. Finally, we suggest adjunctive treatment options for SARS-CoV-2-associated neuro-psychiatric symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.